Study Breakdowns
How to Read a Peptide Study: A Breakdown of the Retatrutide Phase 2 Obesity Trial
TL;DR: In 2023, The New England Journal of Medicine published a Phase 2 randomized controlled trial of retatrutide, an investigational triple-receptor agonist, in adults with obesity. Rather than just report the result, this article uses that paper as a worked example of how to read a clinical study
